HUP0202442A2 - Több citokinből és ellenanyagból álló komplexek - Google Patents

Több citokinből és ellenanyagból álló komplexek

Info

Publication number
HUP0202442A2
HUP0202442A2 HU0202442A HUP0202442A HUP0202442A2 HU P0202442 A2 HUP0202442 A2 HU P0202442A2 HU 0202442 A HU0202442 A HU 0202442A HU P0202442 A HUP0202442 A HU P0202442A HU P0202442 A2 HUP0202442 A2 HU P0202442A2
Authority
HU
Hungary
Prior art keywords
antibody complexes
multiple cytokine
fusion proteins
protein complexes
contain
Prior art date
Application number
HU0202442A
Other languages
English (en)
Inventor
Stephen D. Gillies
Kin Ming Lo
Original Assignee
Lexigen Pharmaceuticals Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharmaceuticals Corp. filed Critical Lexigen Pharmaceuticals Corp.
Publication of HUP0202442A2 publication Critical patent/HUP0202442A2/hu
Publication of HUP0202442A3 publication Critical patent/HUP0202442A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgyát fehérjekomplexek és fúziós fehérjék képezik,amelyek legalább két különböző citokinmolekulát tartalmaznak. Afehérjekomplexek és fúziós fehérjék tartalmazhatnak továbbá célzómolekularészt is, mint például immunglobulin részletét. Afehérjekomplexek és fúziós fehérjék alkalmazására szolgáló eljárásokatis feltárnak. Ó
HU0202442A 1999-08-09 2000-08-09 Multiple cytokine-antibody complexes HUP0202442A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14792499P 1999-08-09 1999-08-09

Publications (2)

Publication Number Publication Date
HUP0202442A2 true HUP0202442A2 (hu) 2002-11-28
HUP0202442A3 HUP0202442A3 (en) 2005-01-28

Family

ID=22523478

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202442A HUP0202442A3 (en) 1999-08-09 2000-08-09 Multiple cytokine-antibody complexes

Country Status (20)

Country Link
US (3) US6617135B1 (hu)
EP (1) EP1200479B1 (hu)
JP (2) JP4793971B2 (hu)
KR (1) KR100827757B1 (hu)
CN (1) CN1235911C (hu)
AT (1) ATE316982T1 (hu)
AU (1) AU778611B2 (hu)
BR (1) BR0013231A (hu)
CA (1) CA2380331C (hu)
DE (1) DE60025832T2 (hu)
DK (1) DK1200479T3 (hu)
ES (1) ES2256027T3 (hu)
HU (1) HUP0202442A3 (hu)
MX (1) MXPA02001417A (hu)
NO (1) NO20020641L (hu)
PL (1) PL202058B1 (hu)
RU (1) RU2263118C2 (hu)
SK (1) SK1842002A3 (hu)
WO (1) WO2001010912A1 (hu)
ZA (1) ZA200200789B (hu)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
JP2002511432A (ja) * 1998-04-15 2002-04-16 レキシジェン ファーマシューティカルズ コーポレイション 新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
CA2372400C (en) * 1999-05-19 2010-04-27 Lexigen Pharmaceuticals Corp. Expression and export of interferon-alpha proteins as fc fusion proteins
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
KR100827757B1 (ko) * 1999-08-09 2008-05-07 메르크 파텐트 게엠베하 복수의 시토킨-항체 복합체
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
ATE336514T1 (de) * 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US20030049689A1 (en) * 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
EP1366067B1 (en) 2001-03-07 2012-09-26 Merck Patent GmbH Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
AU2002308562B2 (en) 2001-05-03 2008-01-24 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US7736657B2 (en) * 2002-02-10 2010-06-15 Apoxis S.A. Fusion constructs containing active sections on TNF ligands
US7736652B2 (en) * 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
US20070003514A1 (en) * 2002-04-05 2007-01-04 The Regents Of The University Of California Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
AU2003243415A1 (en) * 2002-06-07 2003-12-22 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications
US7906118B2 (en) 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
PL211180B1 (pl) 2002-12-17 2012-04-30 Merck Patent Gmbh Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków
WO2004069272A2 (en) * 2003-02-05 2004-08-19 Movecare Ltd Adjuvant combination for use in the immunization of a mamal comprising il2 and il12
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AR046594A1 (es) * 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
DE602004013372T2 (de) * 2003-12-30 2009-07-02 Merck Patent Gmbh Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
JP2008504008A (ja) * 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
DE602005016773D1 (de) * 2004-01-22 2009-11-05 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
US20110064754A1 (en) * 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8034352B2 (en) * 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8003111B2 (en) * 2005-04-06 2011-08-23 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1781684A4 (en) * 2004-08-25 2008-05-21 Amprotein Corp NEW CHIMERE POLYPEPTIDE AND USE THEREOF
KR20070085886A (ko) * 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 감소된 면역원성의 ｉｌ-7 변이체
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
US20060188496A1 (en) * 2005-02-23 2006-08-24 Hanne Bentz Intranasal administration of active agents to the central nervous system
US8158129B2 (en) 2005-04-06 2012-04-17 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
US9623115B2 (en) 2005-04-06 2017-04-18 Ibc Pharmaceuticals, Inc. Dock-and-Lock (DNL) Complexes for Disease Therapy
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
US9931413B2 (en) 2005-04-06 2018-04-03 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP2270050B1 (en) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
WO2007076933A1 (en) * 2005-12-30 2007-07-12 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
WO2009126558A1 (en) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
NZ578065A (en) 2007-01-16 2012-09-28 Abbott Lab Methods for treating psoriasis with an antibody which binds to an epitope
ES2566385T3 (es) * 2007-02-12 2016-04-12 Csl Behring Gmbh Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
KR20100126515A (ko) * 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
RU2498998C2 (ru) * 2008-05-30 2013-11-20 ИксБиотеч, Инк. АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ
WO2010022225A1 (en) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
MX2011008936A (es) 2009-02-24 2011-09-21 Alexion Pharma Inc Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
EA201171259A1 (ru) 2009-04-22 2012-05-30 Мерк Патент Гмбх Антительные гибридные белки с модифицированными сайтами связывания fcrn
NZ607472A (en) * 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
EP2655409A4 (en) 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
CN102221607B (zh) * 2011-03-29 2013-10-02 浙江大学医学院附属第一医院 一种抗体组合物及其应用
CN103930439A (zh) * 2011-05-09 2014-07-16 米纳瓦生物技术公司 基因工程生长因子变异体
EP3626739A1 (en) * 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
RS57480B1 (sr) 2011-11-08 2018-10-31 Umc Utrecht Holding Bv Fuzioni protein koji sadrži interleukin 4 i interleukin 10
TWI487713B (zh) * 2011-12-06 2015-06-11 Nat Univ Chung Hsing 趨化素－細胞素融合蛋白和其應用
KR20150002706A (ko) * 2012-03-29 2015-01-07 알토 바이오사이언스 코포레이션 종양 형성 치료방법
AU2013255542C1 (en) 2012-04-30 2017-06-22 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
AU2012396113B2 (en) * 2012-12-05 2017-03-30 National Chung Hsing University Chemokine-cytokine fusion protein and application thereof
US20160200789A1 (en) * 2013-04-26 2016-07-14 Philogen S.P.A. Il4 conjugated to antibodies against extracellular matrix components
AU2014292371B2 (en) * 2013-07-18 2018-03-29 Centre Hospitalier Regional Universitaire De Montpellier Fusokines involving cytokines with strongly reduced receptor binding affinities
WO2015007520A1 (en) * 2013-07-19 2015-01-22 Vib Vzw Targeting of cytokine antagonists
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
ES2845924T3 (es) 2013-10-15 2021-07-28 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
CA2931299C (en) * 2013-11-20 2024-03-05 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
HUE047806T2 (hu) * 2014-08-29 2020-05-28 Hoffmann La Roche Kombinációs kezelés tumort célzó IL-2-variáns immuncitokinekkel és humán PD-L1 elleni antitestekkel
CN105543279A (zh) * 2014-10-30 2016-05-04 常州卡斯比生物科技有限公司 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
JP2018527350A (ja) * 2015-09-01 2018-09-20 イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． 血餅形成の予防及び／又は血栓症の治療のための分子構築物
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
MX2019001185A (es) * 2016-07-29 2019-10-21 Juno Therapeutics Inc Polipeptidos inmunomoduladores y composiciones y metodos relacionados.
CN110546168B (zh) 2016-09-27 2024-03-15 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
PE20191034A1 (es) 2016-10-14 2019-08-05 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1
US11174306B2 (en) 2016-10-19 2021-11-16 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110573172A (zh) * 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
CN108686202A (zh) 2017-04-06 2018-10-23 张晋宇 肿瘤免疫疗法
EP3630162A1 (en) * 2017-05-24 2020-04-08 Novartis AG Antibody-cytokine engrafted proteins and methods of use
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CA3067909A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
EP3675892A4 (en) 2017-07-03 2021-10-06 Torque Therapeutics, Inc. IMMUNOSTIMULATORY FUSION MOLECULES AND THEIR USES
BR112020006115A2 (pt) 2017-09-27 2020-11-17 Epicentrx, Inc. proteínas de fusão imunomoduladoras
EP3541941A4 (en) * 2017-11-10 2019-12-25 I-Mab Biopharma US Limited FUSION PROTEINS CONTAINING ANTI-CD47 ANTIBODIES AND CYTOKINES
KR20200086722A (ko) 2017-11-21 2020-07-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたｉｌ−２ ｆｃ融合タンパク質
CN112105632A (zh) * 2018-01-24 2020-12-18 北京智康博药肿瘤医学研究有限公司 细胞因子融合蛋白
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
CU24554B1 (es) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
WO2019232523A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
JP7439372B2 (ja) * 2018-06-21 2024-02-28 シャタック ラボ，インコーポレイテッド ヘテロ二量体タンパク質及びその使用
JP2021532796A (ja) * 2018-07-30 2021-12-02 晋宇 張 タンパク質ヘテロ二量体およびその使用
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
MA53862A (fr) 2018-10-12 2022-01-19 Xencor Inc Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
US20220054611A1 (en) * 2018-12-17 2022-02-24 Immune Design Corp. Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
KR102524247B1 (ko) * 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
CN109824786A (zh) * 2019-03-01 2019-05-31 王仁喜 hIL-12p35-Fc融合蛋白、编码基因、重组载体、宿主细胞及应用
CA3137058A1 (en) 2019-04-19 2020-10-22 Synerkine Pharma B.V. A fusion protein comprising il13
CN111848811B (zh) * 2019-04-27 2024-10-01 张晋宇 一种蛋白质异二聚体及其用途
CN111848810B (zh) * 2019-04-28 2024-08-23 张晋宇 一种蛋白质分子及其用途
CN114008082A (zh) * 2019-06-24 2022-02-01 南京金斯瑞生物科技有限公司 单克隆抗体-细胞因子融合蛋白二聚体及其应用
CN112210014B (zh) * 2019-07-12 2022-10-11 北京科诺科服生物科技有限公司 一种用于治疗动物肿瘤的融合蛋白及组合物
CN114466657A (zh) * 2019-07-25 2022-05-10 芝加哥大学 包括蛋白酶激活治疗剂的组合物和方法
CA3157024A1 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CN111303296B (zh) * 2019-12-16 2021-01-29 启辰生生物科技(珠海)有限公司 双功能融合多肽、细胞和药物组合物及应用
AU2021207901A1 (en) 2020-01-14 2022-09-08 Synthekine, Inc. IL2 orthologs and methods of use
KR102653906B1 (ko) 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
WO2021147886A1 (zh) * 2020-01-21 2021-07-29 张晋宇 一种药物组合物及其用途
MX2023000948A (es) 2020-07-20 2023-04-14 Deka Biosciences Inc Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10).
WO2022032040A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb/il2rg synthetic cytokines
WO2022032022A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10 receptor binding molecules and methods of use
US20230399371A1 (en) * 2020-10-29 2023-12-14 Proviva Therapeutics (Hong Kong) Limited Il-12 compositions and methods of use thereof
KR20230123500A (ko) * 2020-12-23 2023-08-23 이뮤노웨이크 인크. 면역사이토카인 및 이의 용도
CA3226163A1 (en) 2021-07-14 2023-01-19 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
CN117957257A (zh) * 2021-08-04 2024-04-30 清华大学 一种靶向并杀伤病原体和/或肿瘤细胞的多功能融合蛋白药物
EP4419545A2 (en) 2021-10-20 2024-08-28 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
CA3240977A1 (en) * 2021-12-16 2023-06-22 John Mumm Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US5082658A (en) 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
EP0158198A1 (en) 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
DE3712985A1 (de) 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
JPS63267278A (ja) 1986-03-14 1988-11-04 Toray Ind Inc インタ−フエロン結合体を暗号化する塩基配列
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5508031A (en) 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US4732683A (en) 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE122238T1 (de) 1987-06-10 1995-05-15 Dana Farber Cancer Inst Inc Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.
DE3880766D1 (de) 1987-09-02 1993-06-09 Ciba Geigy Ag Konjugate von interferon alpha mit immunglobulinen.
ATE108068T1 (de) 1987-09-23 1994-07-15 Bristol Myers Squibb Co Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
DE3812605A1 (de) 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
IL91933A (en) 1988-10-11 1994-12-29 Univ Southern California Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
DE69019609T2 (de) 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DE69030579T2 (de) 1989-09-20 1997-11-13 Abbott Lab Verfahren zur herstellung von fusionsproteinen
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
DK0790308T3 (da) 1989-12-22 2007-10-08 Hoffmann La Roche Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991013166A1 (en) 1990-03-02 1991-09-05 Abbott Biotech, Inc. Antibody constructs with enhanced binding affinity
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
JPH06504262A (ja) 1990-07-27 1994-05-19 レブリゲン　コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
AU651152B2 (en) * 1990-08-29 1994-07-14 Genetics Institute, Llc Multidomain hematopoiesis stimulators
EP1149913A1 (en) * 1990-11-09 2001-10-31 GILLIES, Stephen D. Cytokine immunoconjugates
EP0556328A4 (en) 1990-11-09 1994-06-08 Abbott Lab Bridging antibody fusion constructs
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
WO1993003157A1 (en) 1991-07-29 1993-02-18 Dana Farber Cancer Institute Plasmids for the rapid preparation of modified proteins
DE69227693T2 (de) 1991-08-30 1999-07-22 Fred Hutchinson Cancer Research Center, Seattle, Wash. Hybride cytokine
US20020037558A1 (en) 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US5376367A (en) 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
JP3649335B2 (ja) 1992-04-01 2005-05-18 ザ ロックフェラー ユニバーシティー 樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
DE4228839A1 (de) 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
ATE342356T1 (de) 1992-11-05 2006-11-15 Sloan Kettering Inst Cancer Prostata-spezifisches membranantigen
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
CN1074243A (zh) 1993-02-06 1993-07-14 北京中化生物技术研究所 白介素6-白介素2融合蛋白及其制法和用途
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
HUT73876A (en) 1993-04-29 1996-10-28 Abbott Lab Erythropoietin analog compositions and methods
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
CA2182498A1 (en) 1994-02-01 1995-08-10 William J. Larochelle Fusion proteins that include antibody and nonantibody portions
WO1995028427A1 (en) 1994-04-15 1995-10-26 Imclone Systems Incorporated Chimeric interleukin-3/mutein interleukin-6 lymphokine
BR9507479A (pt) 1994-04-26 1997-09-16 Childrens Medical Center Angipstantina e processo de uso para inibição de angiogenese
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
ATE208633T1 (de) 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
WO1996028548A1 (en) 1995-03-10 1996-09-19 Genentech, Inc. Receptor activation by gas6
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
HUP9802609A2 (hu) 1995-06-30 1999-03-29 Eli Lilly And Co. A diabetes kezelésére szolgáló eljárás
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
JP2000511418A (ja) * 1996-05-20 2000-09-05 シェーリング コーポレイション ヒトインターロイキン―１ｊおよびそのアンタゴニスト
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
ES2176574T3 (es) 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DK0973550T3 (da) 1997-04-11 2003-02-10 Searle & Co Antagonistiske anti-AVB3-integrin-antistoffer
ES2221717T3 (es) * 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
AU764292B2 (en) * 1998-01-23 2003-08-14 Genetics Institute, Llc Method of using IL-11 to enhance cell mediated immunity for treating various viral and parasitic infections and cancer
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
JP2002511432A (ja) * 1998-04-15 2002-04-16 レキシジェン ファーマシューティカルズ コーポレイション 新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強
AU758851B2 (en) * 1998-04-17 2003-04-03 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
US6284536B1 (en) 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
DE69942207D1 (de) * 1998-08-25 2010-05-12 Merck Patent Gmbh Expression und export von angiostatin und endostatin als immunofusins
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
CA2356401A1 (en) * 1999-01-07 2000-07-13 Lexigen Pharmaceuticals, Corp. Expression and export of anti-obesity proteins as fc fusion proteins
EP1178785B1 (en) 1999-05-06 2008-12-24 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
CA2372400C (en) * 1999-05-19 2010-04-27 Lexigen Pharmaceuticals Corp. Expression and export of interferon-alpha proteins as fc fusion proteins
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
KR100827757B1 (ko) 1999-08-09 2008-05-07 메르크 파텐트 게엠베하 복수의 시토킨-항체 복합체
DK1719528T3 (da) * 2000-02-24 2012-01-09 Philogen Spa Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001263149A1 (en) * 2000-05-12 2001-11-26 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
EP1392826A2 (en) * 2001-01-18 2004-03-03 MERCK PATENT GmbH Bifunctional fusion proteins with glucocerebrosidase activity
WO2002066514A2 (en) * 2001-02-19 2002-08-29 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
WO2002069232A2 (en) * 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
EP1366067B1 (en) * 2001-03-07 2012-09-26 Merck Patent GmbH Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
AU2002308562B2 (en) * 2001-05-03 2008-01-24 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity

Also Published As

Publication number Publication date
CN1235911C (zh) 2006-01-11
WO2001010912A1 (en) 2001-02-15
ATE316982T1 (de) 2006-02-15
US6617135B1 (en) 2003-09-09
NO20020641L (no) 2002-04-08
US7141651B2 (en) 2006-11-28
AU778611B2 (en) 2004-12-16
RU2263118C2 (ru) 2005-10-27
EP1200479B1 (en) 2006-02-01
KR100827757B1 (ko) 2008-05-07
JP2003507012A (ja) 2003-02-25
DE60025832D1 (de) 2006-04-13
SK1842002A3 (en) 2003-09-11
CA2380331A1 (en) 2001-02-15
EP1200479A1 (en) 2002-05-02
JP2011067211A (ja) 2011-04-07
PL353348A1 (en) 2003-11-17
PL202058B1 (pl) 2009-05-29
KR20020026368A (ko) 2002-04-09
ZA200200789B (en) 2003-01-29
MXPA02001417A (es) 2002-08-12
CN1382158A (zh) 2002-11-27
US20070258944A1 (en) 2007-11-08
US7582288B2 (en) 2009-09-01
DK1200479T3 (da) 2006-05-15
AU6626800A (en) 2001-03-05
CA2380331C (en) 2012-11-20
BR0013231A (pt) 2002-07-23
US20040072299A1 (en) 2004-04-15
DE60025832T2 (de) 2006-08-31
JP4793971B2 (ja) 2011-10-12
ES2256027T3 (es) 2006-07-16
HUP0202442A3 (en) 2005-01-28
NO20020641D0 (no) 2002-02-08

Similar Documents

Publication Publication Date Title
HUP0202442A2 (hu) Több citokinből és ellenanyagból álló komplexek
TR199902878T2 (xx) Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri.
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
BE2016C015I2 (hu)
NO20054836L (no) Nogo-reseptorbindingsprotein
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DK1093517T3 (da) Neisseria-meningitidis-antigener og præparater
ATE542137T1 (de) Immunocytokine mit modulierter selektivität
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DK1187591T3 (da) IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende samme
DE69839444D1 (de) Smad 6 und dessen anwendungen
WO2003051886A8 (en) Pyrazolopyridazine derivatives
DK1847611T3 (da) Rhamnose-inducerbart ekspressionssystem
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
WO2006028429A3 (en) Peptides for targeting the prostate specific membrane antigen
NO974035L (no) En ny vekstfaktor og en genetisk sekvens som koder for denne
WO2003016551A3 (en) Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof
ATE451454T1 (de) Schnell abgebaute reporter-fusionsproteine
BR9710919A (pt) Proteina purificada sr-p70
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
EP1731531A3 (en) Multiple cytokine-antibody complexes
WO2001002429A3 (en) Angiopoietin-6 and uses thereof